Neurometa Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
Neurometa Therapeutics General Information
Description
Developer of neurodegenerative therapeutics designed to restore neuronal metabolism for disease modification. The company develops treatment candidates addressing metabolic dysfunction, fuel utilization imbalance, mitochondrial activity, and neurodegenerative disorder progression, enabling patients to access interventions targeting underlying biological mechanisms effectively.
Contact Information
Website
www.neurometa.comCorporate Office
- Novi Science Park
- Niels Jernes Vej 10
- 9220 Aalborg
- Denmark
Corporate Office
- Novi Science Park
- Niels Jernes Vej 10
- 9220 Aalborg
- Denmark
Neurometa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC | Cancelled | Generating Revenue | ||||
| 3. Accelerator/Incubator | 10-Oct-2020 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 1. Grant | $80K | Completed | Generating Revenue |
Neurometa Therapeutics Patents
Neurometa Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4370129-A1 | Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject | Pending | 12-Jul-2021 | ||
| WO-2023285349-A1 | Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject | Inactive | 12-Jul-2021 | ||
| AU-2022269825-A1 | Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases | Pending | 04-May-2021 | ||
| CA-3216365-A1 | Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases | Pending | 04-May-2021 | ||
| EP-4334313-A1 | Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases | Pending | 04-May-2021 | C07D417/14 |
Neurometa Therapeutics Signals
Neurometa Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Nordic Mentor Network For Entrepreneurship | Accelerator/Incubator | |||
| BioInnovation Institute | Accelerator/Incubator | Minority | ||
| SmiLe Incubator | Accelerator/Incubator |
Neurometa Therapeutics FAQs
-
When was Neurometa Therapeutics founded?
Neurometa Therapeutics was founded in 2019.
-
Where is Neurometa Therapeutics headquartered?
Neurometa Therapeutics is headquartered in Aalborg, Denmark.
-
What is the size of Neurometa Therapeutics?
Neurometa Therapeutics has 10 total employees.
-
What industry is Neurometa Therapeutics in?
Neurometa Therapeutics’s primary industry is Drug Discovery.
-
Is Neurometa Therapeutics a private or public company?
Neurometa Therapeutics is a Private company.
-
What is Neurometa Therapeutics’s current revenue?
The current revenue for Neurometa Therapeutics is .
-
How much funding has Neurometa Therapeutics raised over time?
Neurometa Therapeutics has raised $1.53M.
-
Who are Neurometa Therapeutics’s investors?
Nordic Mentor Network For Entrepreneurship, BioInnovation Institute, and SmiLe Incubator have invested in Neurometa Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process